Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes

American Journal of Cardiology

Volumn 96, Issue 6 SUPPL., 2005, Pages 47-58

  Bayram, Melike ^a   De Luca, Leonardo ^b   Massie, M Barry ^c   Gheorghiade, Mihai ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCLADESINE; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; IBOPAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART FAILURE SYNDROME; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; FOLLOW UP; HEART LEFT VENTRICLE FILLING PRESSURE; HEART OUTPUT; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOTENSION; LONG TERM CARE; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SUPRAVENTRICULAR PREMATURE BEAT; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 25144443006     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.07.021     Document Type: Article

References (79)

1. American Heart Association Heart Disease and Stroke Statistics - 2005 Update 2005 American Heart Association Dallas, TX
2. K.F. Adams Jr, G.C. Fonarow, C.L. Emerman, T.H. LeJemtel, M.R. Costanzo, W.T. Abraham, R.L. Berkowitz, M. Galvao, D.P. Horton Characteristics and outcomes of patients hospitalized for heart failure in the United States rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 2005 209 216
3. G.C. Fonarow The Acute Decompensated Heart Failure National Registry (ADHERE) opportunities to improve care of patients hospitalized with acute decompensated heart failure Rev Cardiovasc Med 4 suppl 7 2003 S21 S30
4. G.M. Felker, R.L. Benza, A.B. Chandler, J.D. Leimberger, M.S. Cuffe, R.M. Califf, M. Gheorghiade, C.M. O'Connor Heart failure etiology and response to milrinone in decompensated heart failure results from the OPTIME-CHF study J Am Coll Cardiol 41 2003 997 1003
5. S. Thackray, J. Easthaugh, N. Freemantle, J.G. Cleland The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure a meta-regression analysis Eur J Heart Fail 4 2002 515 529
6. C.M. O'Connor, W.A. Gattis, B.F. Uretsky, K.F. Adams Jr, S.E. McNulty, S.H. Grossman, W.J. McKenna, F. Zannad, K. Swedberg, M. Gheorghiade, R.M. Califf Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 138 1999 78 86
7. ADHERE Scientific Advisory Committee, Study Group, and Investigators G.C. Fonarow, C.W. Yancy, J.T. Heywood Adherence to heart failure quality-of-care indicators in US hospitals analysis of the ADHERE registry Arch Intern Med 165 2005 1469 1477
8. K.F. Adams Jr, T. De Marco, R. Berkowitz, S. Chand Inotrope use and negative outcomes in treatment of acute heart failure in patients with preserved systolic function data from the ADHERE database [abstract] Circulation 108 2003 IV-695
9. W.T. Abraham, K.F. Adams Jr, G.C. Fonarow, M.R. Costanzo, R.L. Berkowitz, T.H. Lejemtel, M.L. Cheng, J. Wynne In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 2005 57 64
10. G.W. Dec Acute Decompensated Heart Failure the shrinking role of inotropic therapy J Am Coll Cardiol 46 2005 65 67
11. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.A. Gattis, M. Gheorghiade, B. Greenberg, C.M. O'Connor, C.W. Yancy, J. Young Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) rationale and design Am Heart J 148 2004 43 51
12. G. Fonarow, W.T. Abraham, N. Albert, W. Gattis, M. Gheorghiade, B. Greenberg, C.M. O'Connor, L. She, C.W. Yancy, J.B. Young Impact of evidence-based heart failure therapy use at hospital discharge on treatment rates during follow-up a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) [abstract] J Am Coll Cardiol 45 suppl 2005 345A
13. A.M. Katz A new inotropic drug its promise and a caution N Engl J Med 299 1978 1409 1410
14. M. Packer, N. Medina, M. Yushak Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure Circulation 70 1984 1038 1047
15. M.A. Auerbach, H. Schoder, C. Hoh, S.S. Gambhir, S. Yaghoubi, J.W. Sayre, D. Silverman, M.E. Phelps, H.R. Schelbert, J. Czernin Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy Circulation 99 1999 2921 2926
16. J.G. Cleland, D. Pennel, S. Ray, G. Murray, P. MacFarlane, A. Cowley, A. Coats, A. Lahiri CHRISTMAS Study Steering Committee and Investigators The Carvedilol Hibernation Reversible Ischaemia trial; marker of success (CHRISTMAS) Eur J Heart Fail 1 1999 191 196
17. T. Scarabelli, A. Stephanou, N. Rayment, E. Pasini, L. Comini, S. Curello, R. Ferrari, R. Knight, D. Latchman Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury Circulation 104 2001 253 256
18. W. Wijns, S.F. Vatner, P.G. Camici Hibernating myocardium N Engl J Med 339 1998 173 181
19. H. Lim, J.A. Fallavollita, R. Hard, C.W. Kerr, J.M. Canty Jr Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium Circulation 100 1999 2380 2386
20. K. Shan, R.J. Bick, B.J. Poindexter, S.F. Nagueh, S. Shimoni, M.S. Verani, F. Keng, M.J. Reardon, G.V. Letsou, J.F. Howell, W.A. Zoghbi Altered adrenergic receptor density in myocardial hibernation in humans a possible mechanism of depressed myocardial function Circulation 102 2000 2599 2606
21. R.A. Kloner, K. Przyklenk, B. Patel Altered myocardial states the stunned and hibernating myocardium Am J Med 86 1989 14 22
22. A. Elsasser, M. Schlepper, W.P. Klovekorn, W.J. Cai, R. Zimmermann, K.D. Muller, R. Strasser, S. Kostin, C. Gagel, B. Munkel, W. Schaper, J. Schaper Hibernating myocardium an incomplete adaptation to ischemia Circulation 96 1997 2920 2931
23. R. Schulz, B.D. Guth, K. Pieper, C. Martin, G. Heusch Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery a model of short-term hibernation Circ Res 70 1992 1282 1295
24. R. Schulz, J. Rose, C. Martin, O.E. Brodde, G. Heusch Development of short-term myocardial hibernation its limitation by the severity of ischemia and inotropic stimulation Circulation 88 1993 684 695
25. L.M. Buja, M.L. Entman Modes of myocardial cell injury and cell death in ischemic heart disease Circulation 98 1998 1355 1357
26. F.A. Chaudhry, J.T. Tauke, R.S. Alessandrini, G. Vardi, M.A. Parker, R.O. Bonow Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction J Am Coll Cardiol 34 1999 730 738
27. J.G. Hardman, L.E. Limbird, A.G. Gilman Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001 The McGraw-Hill Companies, Inc Columbus, OH 1825
28. A.M. Katz Cellular mechanisms in congestive heart failure Am J Cardiol 62 suppl 1988 3A 8A
29. A.M. Katz Is the failing heart energy depleted? Cardiol Clin 16 1998 633 644 viii
30. 2 utilization in heart failure Cardiovasc Res 53 2002 392 404
31. 2 cost of catecholamines in heart failure) Eur J Heart Fail 6 2004 409 419
32. T. Nanbu, T. Nakakoshi, K. Yonezawa, A. Kitabatake Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload Am Heart J 138 1999 641 645
33. R.S. Beanlands, D.S. Bach, R. Raylman, W.F. Armstrong, V. Wilson, M. Montieth, C.K. Moore, E. Bates, M. Schwaiger Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy J Am Coll Cardiol 22 1993 1389 1398
34. H. Hashimoto, S. Kunitada, K. Tamura Functional and metabolic effects of bucladesine (dibutyryl cyclic AMP) in the working rat heart preparation comparison with dopamine Arch Int Pharmacodyn Ther 301 1989 200 214
35. E.S. Monrad, D.S. Baim, H.S. Smith, A.S. Lanoue Milrinone, dobutamine, and nitroprusside comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure Circulation 73 1986 III168 III174
36. H.D. White, J.P. Ribeiro, L.H. Hartley, W.S. Colucci Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure Am J Cardiol 56 1985 93 98
37. C.S. Liang, L.G. Sherman, J.U. Doherty, K. Wellington, V.W. Lee, W.B. Hood Jr Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine Circulation 69 1984 113 119
38. A. Mebazaa, D. Barraud, S. Welschbillig Randomized clinical trials with levosimendan Am J Cardiol 96 suppl 6A 2005 74G 79G
39. F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, V.P. Harjola, V. Mitrovic, M. Abdalla, E.P. Sandell, L. Lehtonen Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) a randomised double-blind trial Lancet 360 2002 196 202
40. M.N. Zairis, C. Apostolatos, F. Anastassiadis, N.. Kouris, H. Grassos, M. Sifaki, D. Babalis, S. Foussas Comparison of the effect of levosimendan, or dobutamine or placebo in chronic low output decompensated heart failure. CAlcium Sensitizer or Inotrope or NOne in low output heart failure (CASINO) study Program and abstracts of the European Society of Cardiology, Heart Failure Update 2004 2004 June 12-15; Wroclaw, Poland. Abstract 273
41. A.P. Coletta, J.G. Cleland, N. Freemantle, A.L. Clark Clinical trials update from the European Society of Cardiology Heart Failure meeting SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO, and meta-analysis of cardiac resynchronisation therapy Eur J Heart Fail 6 2004 673 676
42. A. Mebazaa, A. Cohen-Solal, F.X. Kleber, M. Nieminen, M. Packer, S.J. Pocock, P. Poder, T. Sarapohja, M. Kivikko Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure [abstract] Crit Care 8 suppl 1 2004 P87
43. M. Packer, J.R. Carver, R.J. Rodeheffer, R.J. Ivanhoe, R. DiBianco, S.M. Zeldis, G.H. Hendrix, W.J. Bommer, U. Elkayam, M.L. Kukin PROMISE Study Research Group Effect of oral milrinone on mortality in severe chronic heart failure N Engl J Med 325 1991 1468 1475
44. M.S. Cuffe, R.M. Califf, K.F. Adams Jr, R. Benza, R. Bourge, W.S. Colucci, B.M. Massie, C.M. O'Connor, I. Pina, R. Quigg, M.A. Silver, M. Gheorghiade Short-term intravenous milrinone for acute exacerbation of chronic heart failure a randomized controlled trial JAMA 287 2002 1541 1547
45. J.L. Anderson Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure results of a multicenter study in the United States Am Heart J 121 1991 1956 1964
46. J.L. Anderson, D.S. Baim, S.A. Fein, R.A. Goldstein, T.H. LeJemtel, M.J. Likoff Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure a multicenter study J Am Coll Cardiol 9 1987 711 722
47. Y. Seino, S. Momomura, T. Takano, H. Hayakawa, K. Katoh Japan Intravenous Milrinone Investigators Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan Crit Care Med 24 1996 1490 1497
48. M.M. McDermott, J. Feinglass, P.I. Lee, S. Mehta, B. Schmitt, F. Lefevre, M. Gheorghiade Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure Am Heart J 134 1997 728 736
49. T.L. Biddle, J.R. Benotti, M.A. Creager, D.P. Faxon, B.G. Firth, P.G. Fitzpatrick, M.A. Konstam, C. Krebs, L. Walton, R.P. Kershner Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy Am J Cardiol 59 1987 1345 1350
50. E.J. Eichhorn, M.A. Konstam, D.S. Weiland, D.J. Roberts, T.T. Martin, N.B. Stransky, D.N. Salem Differential effects of milrinone and dobutamine on right ventricular preload, afterload, and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 60 1987 1329 1333
51. R.P. Karlsberg, M.A. DeWood, A.N. DeMaria, M.R. Berk, K.P. Lasher Milrinone-Dobutamine Study Group Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction Clin Cardiol 19 1996 21 30
52. R.O. Feneck, K.M. Sherry, P.S. Withington, A. Oduro-Dominah Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery J Cardiothorac Vasc Anesth 15 2001 306 315
53. J.M. Aranda Jr, R.S. Schofield, D.F. Pauly, T.S. Cleeton, T.C. Walker, V.S. Monroe Jr, D. Leach, L.M. Lopez, J.A. Hill Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation a prospective, randomized trial Am Heart J 145 2003 324 329
54. W.J. Remme Inodilator therapy for heart failure early, late, or not at all? Circulation 87 1993 IV97 IV107
55. C. Oakley Genesis of arrhythmias in the failing heart and therapeutic implications Am J Cardiol 67 suppl 1991 26C 28C
56. 2+/calmodulin-dependent protein kinase is altered in heart failure Circ Res 86 2000 596 605
57. 2+-handling proteins and heart failure novel molecular targets? Curr Med Chem 10 2003 967 981
58. M.R. Bristow Beta-adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569
59. M. Gheorghiade, W.S. Colucci, K. Swedberg Beta-blockers in chronic heart failure Circulation 107 2003 1570 1575
60. M. Metra, S. Nodari, A. D'Aloia, C. Muneretto, A.D. Robertson, M.R. Bristow, L. Dei Cas Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol J Am Coll Cardiol 40 2002 1248 1258
61. W.S. Colucci, R.F. Wright, E. Braunwald New positive inotropic agents in the treatment of congestive heart failure mechanisms of action and recent clinical developments N Engl J Med 314 1986 290 299
62. B.D. Lowes, M.A. Simon, T.O. Tsvetkova, M.R. Bristow Inotropes in the beta-blocker era Clin Cardiol 23 2000 III11 III16
63. B.D. Lowes, T. Tsvetkova, E.J. Eichhorn, E.M. Gilbert, M.R. Bristow Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol Int J Cardiol 81 2001 141 149
64. S.F. Shakar, W.T. Abraham, E.M. Gilbert, A.D. Robertson, B.D. Lowes, L.S. Zisman, D.A. Ferguson, M.R. Bristow Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure J Am Coll Cardiol 31 1998 1336 1340
65. T. Yoshikawa, A. Baba, M. Suzuki, H. Yokozuka, Y. Okada, K. Nagami, T. Takahashi, H. Mitamura, S. Ogawa Keio Interhospital Cardiology Study (KICS) Group Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure Am J Cardiol 85 2000 1495 1497 A1497
66. A. Kumar, G. Choudhary, C. Antonio, V. Just, A. Jain, L. Heaney, M.A. Papp Carvedilol titration in patients with congestive heart failure receiving inotropic therapy Am Heart J 142 2001 512 515
67. L.W. Stevenson Clinical use of inotropic therapy for heart failure looking backward or forward? Part II: chronic inotropic therapy Circulation 108 2003 492 497
68. C.V. Leier, P. Huss, R.P. Lewis, D.V. Unverferth Drug-induced conditioning in congestive heart failure Circulation 65 1982 1382 1387
69. F. Dies, M.J. Krell, P. Whitlow Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure Circulation 74 suppl II 1986 II-38
70. H.H. Erlemeier, W. Kupper, W. Bleifeld Intermittent infusion of dobutamine in the therapy of severe congestive heart failure long-term effects and lack of tolerance Cardiovasc Drugs Ther 6 1992 391 398
71. S. Adamopoulos, M. Piepoli, F. Qiang, E. Pissimissis, M. Davies, L. Bernardi, C. Forfar, P. Sleight, A. Coats Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure Lancet 345 1995 344 349
72. F. Oliva, R. Latini, A. Politi, L. Staszewsky, A.P. Maggioni, E. Nicolis, F. Mauri Intermittent 6-month low-dose dobutamine infusion in severe heart failure DICE multicenter trial Am Heart J 138 1999 247 253
73. A. Elis, T. Bental, O. Kimchi, M. Ravid, M. Lishner Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure a randomized, double-blind, placebo-controlled study Clin Pharmacol Ther 63 1998 682 685
74. J. Lubsen, H. Just, A.C. Hjalmarsson, D. La Framboise, W.J. Remme, J. Heinrich-Nols, J.M. Dumont, P. Seed Effect of pimobendan on exercise capacity in patients with heart failure main results from the Pimobendan in Congestive Heart Failure (PICO) trial Heart 76 1996 223 231
75. J.R. Hampton, D.J. van Veldhuisen, F.X. Kleber, A.J. Cowley, A. Ardia, P. Block, A. Cortina, L. Cserhalmi, F. Follath, G. Jensen Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure Lancet 349 1997 971 977
76. J.N. Cohn, S.O. Goldstein, B.H. Greenberg, B.H. Lorell, R.C. Bourge, B.E. Jaski, S.O. Gottlieb, F. McGrew III, D.L. DeMets, B.G. White Vesnarinone Trial Investigators A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure N Engl J Med 339 1998 1810 1816
77. R.M. Califf, K.F. Adams Jr, W.J. McKenna, M. Gheorghiade, B.F. Uretsky, S.E. McNulty, H. Darius, K. Schulman, F. Zannad, E. Handberg-Thurmond A randomized controlled trial of epoprostenol therapy for severe congestive heart failure the Flolan International Randomized Survival Trial (FIRST) Am Heart J 134 1997 44 54
78. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S. Francis, T.G. Ganiats, S. Goldstein, G. Gregoratos, M.L. Jessup ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America Circulation 104 2001 2996 3007
79. M.S. Nieminen, M. Bohm, M.R. Cowie, H. Drexler, G.S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, A. Mebazaa, M. Metra Executive summary of the Guidelines on the Diagnosis and Treatment of Acute Heart Failure the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 384 416